• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.

作者信息

Janssen Marlou T H F, Ramiro Sofia, Landewé Robert B M, Magro-Checa César, Mostard Rémy L M

机构信息

Pulmonology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands

Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.

出版信息

Ann Rheum Dis. 2021 Oct;80(10):1362-1363. doi: 10.1136/annrheumdis-2021-220040. Epub 2021 May 6.

DOI:10.1136/annrheumdis-2021-220040
PMID:33958327
Abstract
摘要

相似文献

1
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.接受糖皮质激素联合或不联合托珠单抗治疗COVID-19相关过度炎症的患者对SARS-CoV-2的抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1362-1363. doi: 10.1136/annrheumdis-2021-220040. Epub 2021 May 6.
2
COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.COVID-19 引起的过度炎症、免疫抑制、恢复和存活：因果推断如何帮助得出可靠的结论。
RMD Open. 2021 Mar;7(1). doi: 10.1136/rmdopen-2021-001638.
3
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.白细胞介素-6阻断治疗用于一名慢性髓性白血病控制不佳患者的新型冠状病毒肺炎相关细胞因子释放综合征
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.
4
A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.回顾性匹配队列单中心研究评估了 COVID-19 的结果以及免疫调节对实体器官移植受者 COVID-19 相关细胞因子释放综合征的影响。
Transpl Infect Dis. 2021 Apr;23(2):e13556. doi: 10.1111/tid.13556. Epub 2021 Jan 22.
5
Is IL-6 a key cytokine target for therapy in COVID-19?白细胞介素-6 是 COVID-19 治疗的关键细胞因子靶点吗？
Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8.
6
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.托珠单抗在 SARS-CoV-2 诱导的细胞因子风暴中的治疗作用：原理和现有证据。
Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059.
7
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.为何选择环孢素A作为新冠肺炎的一线治疗药物。
Reumatol Clin (Engl Ed). 2021 Nov;17(9):556-557. doi: 10.1016/j.reumae.2020.03.005.
8
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
9
Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.托珠单抗联合糖皮质激素治疗重症和危重症 COVID-19 患者：单中心经验
Med Clin (Barc). 2020 Nov 13;155(9):410-411. doi: 10.1016/j.medcli.2020.07.001. Epub 2020 Jul 9.
10
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.视神经脊髓炎谱系障碍患者在新冠疫情期间的免疫抑制：一项新挑战。
Mult Scler Relat Disord. 2020 Jun;41:102097. doi: 10.1016/j.msard.2020.102097. Epub 2020 Apr 5.

引用本文的文献

1
Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）诱导的细胞因子风暴管理中的特定检查点
Life (Basel). 2022 Mar 25;12(4):478. doi: 10.3390/life12040478.
2
Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study.COVID-19 相关性过度炎症患者接受短期免疫抑制治疗的 3 个月和 6 个月结局：CHIC 研究的随访。
RMD Open. 2021 Nov;7(3). doi: 10.1136/rmdopen-2021-001906.